Published in Heart Disease Weekly, December 15th, 2002
The renewal allows CryoLife, a pioneer in implantable tissues and surgical adhesives, to continue processing and distributing its cardiac and vascular tissue under the terms of the original agreement for an additional 45 working days, ending January 15, 2003, or until a reinspection is executed and an outcome determined.
As required under terms of the September 5, 2002, interim agreement, CryoLife submitted its corrective action plan on October 5, 2002, to the FDA and has requested an FDA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.